Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
fecal microbiome filtrate
- Development stage
- Unknown
- Lead developer
- Friedrich Schiller University Jena
- Modality
- Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Administration
- Oral
01
Overview
Fecal microbiome filtrate (FMF) is a sterile, cell-free liquid preparation derived from healthy donor stool. Unlike conventional Fecal Microbiota Transplantation (FMT), which transfers live microbes, the filtrate is processed to remove bacteria and other particulate matter. It contains soluble components from the gut microbiome, such as metabolites, bacteriophages (viruses that infect bacteria), and other microbial-derived signaling molecules. [2, 3] The therapeutic principle is that these non-cellular elements can modulate the recipient's gut environment and immune system to restore homeostasis, without the risks associated with transplanting live bacteria. [2, 6] It is being investigated by institutions like Friedrich-Schiller-Universitaet Jena for the treatment of inflammatory bowel diseases, such as ulcerative colitis. [5]
- Other names
- faecal microbiota filtratesterile fecal filtrateFMF
Beyond the preview
Go deeper on fecal microbiome filtrate.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on fecal microbiome filtrate.